INMB Stock Price, Inmune Bio Inc Quote, Chart

Market Summary

USD10.81-0.36

Delayed

-3.22%

INMB Alerts

4 major insider buys recently.

INMB Stock Price

View Fullscreen

INMB RSI Chart

INMB Valuation

Market Cap

196.8M

Price/Earnings (Trailing)

-5.7

Price/Sales (Trailing)

1.5K

Price/Free Cashflow

-10.74

INMB Price/Sales (Trailing)

INMB Profitability

Return on Equity

-122.23%

Return on Assets

-73.66%

Free Cashflow Yield

-9.31%

INMB Fundamentals

INMB Revenue

Revenue (TTM)

131.0K

Rev. Growth (Yr)

-63.16%

Rev. Growth (Qtr)

-50%

INMB Earnings

Earnings (TTM)

-34.5M

Earnings Growth (Yr)

-68.68%

Earnings Growth (Qtr)

-31.13%

Breaking Down INMB Revenue

Last 7 days

7.9%

Last 30 days

28.2%

Last 90 days

-22.8%

Trailing 12 Months

50.6%

How does INMB drawdown profile look like?

INMB Financial Health

Current Ratio

1.71

INMB Investor Care

Shares Dilution (1Y)

1.43%

Diluted EPS (TTM)

-1.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	131.0K	0	0	0
2023	249.0K	279.0K	224.0K	155.0K
2022	340.0K	356.0K	440.0K	374.0K
2021	53.5K	96.0K	138.5K	181.0K
2020	0	0	0	11.0K
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Inmune Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	lowdell mark william	bought	119,999	8.32	14,423	chief scientific officer
Apr 19, 2024	moss david j	acquired	149,993	8.32	18,028	cfo, treasurer & secretary
Apr 19, 2024	moss david j	bought	149,993	8.32	18,028	cfo, treasurer & secretary
Apr 19, 2024	lowdell mark william	acquired	119,999	8.32	14,423	chief scientific officer
Apr 19, 2024	juda scott	bought	246,297	8.32	29,603	-
Apr 19, 2024	tesi raymond joseph	bought	149,993	8.32	18,028	president and ceo
Apr 19, 2024	tesi raymond joseph	acquired	149,993	8.32	18,028	president and ceo
Apr 19, 2024	juda scott	acquired	246,297	8.32	29,603	-
Nov 10, 2023	juda scott	bought	48,650	6.95	7,000	-
Jul 12, 2023	schroeder timothy j	sold	-110,085	11.0085	-10,000	-

Which funds bought or sold INMB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	71.49	383,458	869,147	-%
May 15, 2024	Royal Bank of Canada	added	43.16	322,000	973,000	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-99.91	-380,809	353	-%
May 15, 2024	DEUTSCHE BANK AG\	unchanged	-	53,826	1,290,710	-%
May 15, 2024	Laird Norton Wetherby Trust Company, LLC	unchanged	-	15,435	370,125	0.05%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-37.86	-55,865	103,024	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	9,400	9,400	-%
May 15, 2024	STATE STREET CORP	unchanged	-	22,081	529,490	-%
May 15, 2024	MORGAN STANLEY	added	114	178,717	322,879	-%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	157,897	157,897	0.04%

Are Funds Buying or Selling INMB?

Are funds buying INMB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INMB

No. of Funds

INMB Alerts

4 major insider buys recently.

Unveiling Inmune Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 15, 2023	xencor inc	10.5%	1,885,533	SC 13G
Apr 21, 2022	tesi raymond joseph	11.6%	2,155,403	SC 13D/A
Apr 21, 2022	lowdell mark william	11.1%	2,046,383	SC 13D/A
Apr 21, 2022	moss david j	10.1%	1,882,956	SC 13D/A
Feb 14, 2022	altium capital management lp	0%	0	SC 13G/A
Jul 19, 2021	altium capital management lp	5.1%	909,091	SC 13G
Jan 22, 2021	xencor inc	12.5%	1,690,000	SC 13G/A
Feb 14, 2020	xencor inc	15.3%	1,654,000	SC 13G
Feb 14, 2020	moss david j	14.82%	1,656,750	SC 13D/A
Feb 14, 2020	lowdell mark william	17.25%	1,926,251	SC 13D/A

Recent SEC filings of Inmune Bio Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	8-K	Current Report
May 13, 2024	8-K	Current Report

Peers (Alternatives to Inmune Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Inmune Bio Inc News

Latest updates

Inmune Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q2
Revenue	-50.0%	14.00	28.00	43.00	46.00	38.00	97.00	98.00	16.00	163	163	14.00	-	4.00	20.00	36.00
Operating Expenses	31.2%	11,031	8,407	8,571	6,457	6,461	5,739	7,541	6,404	6,641	9,193	9,035	6,554	4,552	3,220	428
S&GA Expenses	-100.0%	-	2,400	2,586	2,309	2,328	2,329	2,382	2,215	2,332	2,125	2,515	2,090	2,061	1,361	1,336
R&D Expenses	44.7%	8,693	6,007	5,985	4,148	4,133	3,410	5,159	4,189	4,309	7,068	6,520	4,464	2,491	1,859	635
Interest Expenses	-21.4%	302	384	464	480	450	410	361	310	291	294	265	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-31.1%	-11,025	-8,408	-8,563	-6,501	-6,536	-5,833	-7,725	-6,838	-6,903	-9,671	-9,458	-6,655	-4,556	-3,204	-392
Net Income Margin	-36.0%	-263.34*	-193.60*	-122.47*	-95.32*	-108.16*	-72.99*	-70.77*	-92.33*	-96.14*	-167.62*	-172.37*	-199.29*	-272.62*	-	-
Free Cashflow	-119.8%	-7,476	-3,401	-4,264	-3,174	-1,141	-5,695	-3,367	-4,759	-8,865	-9,780	-7,923	-5,709	-5,092	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-17.8%	47.00	57.00	63.00	70.00	74.00	82.00	84.00	88.00	94.00	100	108	61.00	66.00	41.00	43.00	23.00	24.00	24.00	25.00	28.00	24.00
Current Assets	-25.3%	30.00	40.00	46.00	53.00	57.00	65.00	67.00	71.00	77.00	83.00	91.00	44.00	49.00	24.00	26.00	6.00	7.00	8.00	9.00	11.00	7.00
Cash Equivalents	-27.5%	26.00	36.00	42.00	48.00	51.00	52.00	57.00	61.00	67.00	75.00	84.00	40.00	45.00	22.00	24.00	5.00	6.00	7.00	7.00	9.00	6.00
Liabilities	-5.6%	18.00	19.00	18.00	19.00	19.00	22.00	20.00	18.00	19.00	20.00	19.00	17.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
Current Liabilities	-5.5%	17.00	18.00	14.00	13.00	10.00	11.00	7.00	2.00	3.00	4.00	5.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	-
LT Debt, Current	-24.9%	7.00	10.00	-	-	-	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-24.4%	28.00	37.00	44.00	51.00	55.00	60.00	64.00	70.00	76.00	80.00	88.00	43.00	64.00	39.00	41.00	22.00	22.00	24.00	25.00	27.00	23.00
Retained Earnings	-9.1%	-132	-121	-112	-104	-97.55	-91.00	-85.18	-77.46	-70.62	-63.71	-54.04	-44.59	-37.93	-33.37	-30.17	-25.45	-23.35	-21.28	-18.96	-15.89	-15.50
Additional Paid-In Capital	1.1%	161	159	157	155	154	152	150	148	146	144	142	88.00	101	72.00	71.00	47.00	46.00	45.00	44.00	43.00	34.00
Shares Outstanding	0.4%	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	17.00	15.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	106	-	-	-	103	-	-	-	157	-	-	-	0.00	-	-	-	35.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-119.8%	-7,476	-3,401	-4,264	-3,174	-1,141	-5,695	-3,367	-4,759	-8,865	-9,780	-7,923	-5,709	-5,092	-2,392	-3,698	-1,818	-1,035	-433	-1,945	-1,617	-1,387
Share Based Compensation	-5.3%	1,779	1,879	1,889	1,863	1,737	1,788	1,939	1,886	1,536	1,522	1,606	769	899	703	1,046	682	682	1,172	975	975	975
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	0%	-2,500	-2,500	-	-	-	-	-	-	729	-	52,942	14,951	28,464	-	23,240	664	-9.00	-	-	4,958	7,251

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INMB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
REVENUE	$ 14	$ 38
OPERATING EXPENSES
General and administrative	2,338	2,328
Research and development	8,693	4,133
Total operating expenses	11,031	6,461
LOSS FROM OPERATIONS	(11,017)	(6,423)
OTHER EXPENSE, NET	(8)	(113)
NET LOSS	$ (11,025)	$ (6,536)
Net loss per common share – basic (in Dollars per share)	$ (0.61)	$ (0.36)
Weighted average common shares outstanding – basic (in Shares)	18,026,473	17,945,995
COMPREHENSIVE LOSS
Net loss	$ (11,025)	$ (6,536)
Other comprehensive income (loss) – foreign currency translation	130	(9)
Total comprehensive loss	$ (10,895)	$ (6,545)

INMB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 26,002	$ 35,848
Research and development tax credit receivable	2,133	1,905
Other tax receivable	557	537
Prepaid expenses and other current assets	1,109	1,510
TOTAL CURRENT ASSETS	29,824	39,942
Operating lease – right of use asset	389	414
Other assets	106	131
Acquired in-process research and development intangible assets	16,514	16,514
TOTAL ASSETS	46,833	57,001
CURRENT LIABILITIES
Accounts payable and accrued liabilities	9,294	7,901
Deferred liabilities	520	489
Current portion of long-term debt	7,455	9,921
Operating lease, current liabilities	125	119
TOTAL CURRENT LIABILITIES	17,450	18,465
Long-term operating lease liability	360	397
TOTAL LIABILITIES	17,810	18,862
COMMITMENTS AND CONTINGENCIES
Redeemable common stock, $0.001 par value; 75,697 issued and outstanding, respectively (Note 9)	799	799
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.001 par value, 200,000,000 shares authorized, 17,950,776 shares issued and outstanding, respectively	18	18
Additional paid-in capital	160,922	159,143
Accumulated other comprehensive loss	(669)	(799)
Accumulated deficit	(132,047)	(121,022)
TOTAL STOCKHOLDERS’ EQUITY	28,224	37,340
TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY	46,833	57,001
Related Party
CURRENT ASSETS
Prepaid expenses – related party	23	142
CURRENT LIABILITIES
Accounts payable and accrued liabilities – related parties	$ 56	$ 35

About Inmune Bio Inc

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

CEO	Dr. Raymond Joseph Tesi M.D.
WEBSITE	inmunebio.com
INDUSTRY	Biotechnology
EMPLOYEES	10

Inmune Bio Inc Frequently Asked Questions

What is the ticker symbol for Inmune Bio Inc? What does INMB stand for in stocks?

INMB is the stock ticker symbol of Inmune Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inmune Bio Inc (INMB)?

As of Fri May 17 2024, market cap of Inmune Bio Inc is 196.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INMB stock?

You can check INMB's fair value in chart for subscribers.

What is the fair value of INMB stock?

You can check INMB's fair value in chart for subscribers. The fair value of Inmune Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inmune Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INMB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inmune Bio Inc a good stock to buy?

The fair value guage provides a quick view whether INMB is over valued or under valued. Whether Inmune Bio Inc is cheap or expensive depends on the assumptions which impact Inmune Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INMB.

What is Inmune Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, INMB's PE ratio (Price to Earnings) is -5.7 and Price to Sales (PS) ratio is 1.5 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INMB PE ratio will change depending on the future growth rate expectations of investors.